focus -WSS

focus

author：knowledge 2025-09-30 22:07:46 - browse：3172

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Goldman Sachs launches $650M fund for life science investments

leisure time

WSS

Feng Zhang CRISPR delivery startup lays off quarter of staff

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Feng Zhang CRISPR delivery startup lays off quarter of staff

Congress must reauthorize a committee to support older Americans

David Sabatini, ex

Wegovy, Zepbound and weight loss drugs that preserve muscle

knowledge

focus

Wikipedia

What does generative AI mean for health care? We asked experts

Antibiotic resistance and the global rise in human conflict

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Virginia high school admissions case could be legal follow

Poor hospice wound care hurts patients and families

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

United colonoscopy coverage change 'may cost lives,' doctors say

A daunting task: navigating dual Medicare, Medicaid eligibility

knowledge

CRISPR pioneers react to Casgevy, first gene

U.K. considers world's first use of meningitis vaccine to address gonorrhea

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

A single drug, study failures leave Anavex with nothing but cash

White House finalizes ITC's import ban of latest Apple Watches

hotspot

entertainment

leisure time

focus